BAKER & MCKENZIE LLP: Lundbeck to Acquire Alder BioPharmaceuticals


Baker & McKenzie LLP issued the following announcement on Sept. 24.

Baker McKenzie partners with Lundbeck in-house legal team on the $1.95 Billion Transaction

Baker McKenzie is advising global pharmaceutical company Lundbeck on the acquisition of Alder BioPharmaceuticals, a company committed to migraine treatment and prevention. The transaction is valued up to $1.95 billion net of cash, on a fully diluted basis.

This acquisition will further enhance Lundbeck's capabilities to deliver future biological innovations in brain diseases. The addition of eptinezumab, which Alder is developing for preventive migraine treatment, will expand Lundbeck’s leading global brain disease franchise.

Lundbeck's in-house legal team advising on the transaction was led by Lundbeck's general counsel Søren Hoffmann, and includes Allan Normann, Thomas Forrester and Colleen Hickey.

Baker McKenzie's team advising Lundbeck is led by Thomas Hughes, M&A, and Randall Sunberg, North America Life Science Practice Co-Head, and includes Piotr Korzynski, Jonathan Farrokhnia, Geoffrey Hainbach, Collin Stich and Rebecca Chang (M&A), Andrew Haupt (Life Sciences), Craig Roeder and Michael Hamilton (Capital Markets), Dr. Jur Strobos and Thilo Raepple (Regulatory), Pamela Church, Heiko Burow and Jessica Greenwald (Intellectual Property), Maura Ann McBreen and Carole Spink (Employee Benefits and Labor), Creighton Macy, Christian Burholdt and Andreas Traugott (Antitrust), and Kai Kramer and Ross Staine (Tax).

Baker McKenzie's Healthcare and Life Sciences group advises many of the world's largest pharmaceutical, biotech, medical device and healthcare services companies on a range of issues including transactional matters, patents and brands, global transfer pricing and tax planning strategies, product liability, competition and trade, commercial agreements, data privacy, employment issues and market entry.

This year, LMG Life Sciences, a guide to the leading North American law firms in the industry, named Baker McKenzie a 2019 Financial & Corporate Firm to Watch, noting our work in licensing, collaboration, M&A and venture capital.

Original source can be found here.

Want to get notified whenever we write about Baker & McKenzie LLP ?

Sign-up Next time we write about Baker & McKenzie LLP, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Baker & McKenzie LLP

More News

Metro Business Network